Loading clinical trials...
Loading clinical trials...
A Phase II Randomized Study of Sipuleucel-T With or Without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer With PSA Progression While on NHA and LHRH Analog
Conditions
Interventions
Abiraterone
Enzalutamide
+2 more
Locations
2
United States
Moffitt Cancer Center
Tampa, Florida, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Start Date
February 14, 2023
Primary Completion Date
October 1, 2026
Completion Date
December 1, 2026
Last Updated
March 16, 2026
NCT06594926
NCT06257264
NCT03620786
NCT05939414
NCT05424783
NCT04693377
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions